Clinical trials recruiting: Molluscum contagiousum

Physicians throughout the country are recruiting patients for two phase three clinical trials of cantharidin for the treatment of molluscum contagiousum. a viral skin condition.

The trials, CAMP-1 and CAMP-2, are randomized, double-blind, placebo-controlled of VP-102, a .7% cantharidin formulation administered with a single-use applicator.

In CAMP-1 and 2, VP-102 will be applied once every 21 days for up to four applications for patients two miryears old or older. It will be compared to a placebo group and efficacy will be assessed on day 84.

“Although cantharidin has been used extensively for decades in the treatment of dermatologic conditions molluscum and verruca vulgaris, specifications for the quality of the active pharmaceutical ingredient and a standardized formulation and dosing regimen have never been established. To date, cantharidin remains an unapproved drug in the US,” said Verrica Pharmaceuticals, a trial sponsor, stated in a news release.
For more information, CAMP-1,http://bit.ly/CAMP1Trial; CAMP-2, http://bit.ly/CAMP2Trial

Lawrence Eichenfield, M.D., Rady Children's Hospital, San Diego, is the principal investigator of both studies.

In addition to Verrica, the sponsors and collaborators of both studies include Instat Consulting, Inc., Paidion Research, Inc. and Database Integrations.